Ioana Crisan

Great speaking with Florence Vuichard and Pascal Michel for a story in today's "Schweiz am Wochenende". We talked about medicines people urgently need and sometimes cannot get, because current supplies are in different pack sizes than prescribed or because they are warehoused in different countries from which they cannot be imported due to regulatory hurdles. In my view there would be an easy solution: liberalilze the pharmaceutical supply chain accross borders and agree on prices that reflect the true value of essential generic medicines. We also spoke about the medicines everybody wants but nobody can produce enough of: weight-loss drugs. While this is a unique market situation like I have never seen before, we also need address rising environmental concerns with a dramatically growing number of one-time application devices.

254

10 Kommentare

Keeping young minds fizzing with ideas long into the future, to inspire the next generation of curious minds, here are some top picks for science books for kids and young adults.

2

💸 𝐖𝐡𝐢𝐜𝐡 𝐝𝐫𝐮𝐠𝐬 𝐰𝐢𝐥𝐥 𝐥𝐨𝐬𝐞 𝐩𝐚𝐭𝐞𝐧𝐭𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐜𝐨𝐦𝐢𝐧𝐠 𝐲𝐞𝐚𝐫𝐬? A great overview by Joanna Sadowska, PhD, EMBA - many thanks for this superb work! ⚆ Nearly 200 drugs are going off-patent in the near future ⚆ These include at least 69 blockbusters (>$1B in annual sales) ⚆ This could lead to over 49% revenue decline for major companies The pharmaceutical industry is staring down a major patent cliff, with more than $300B in sales at risk in coming years. Unlike the previous patent cliff, this one includes a fair number of biologics, making the transition to biosimilars highly relevant. Navigating this coming cliff will require a combination of innovation and strategy from the pharmaceutical industry. As patents near their end, maintaining the market position of your drug product becomes a pressing challenge. But with innovative formulation strategies, it’s possible to extend the lifecycle of your product while adding value for patients and healthcare providers. 💡 How Glatt Pharmaceutical Services - CDMO Unlimited can help in the area of oral solid dosage forms: ✅ Controlled Release Formulations: Deliver sustained therapeutic effects, improve patient compliance, and stand out in the marketplace. ✅ Orally Disintegrating Tablets (ODTs): Create patient-friendly options, especially for those with swallowing difficulties. ✅ Layered Tablets or Multi-Particulates: Optimize release profiles and combine APIs for unique therapeutic benefits. ✅ Technology Upgrades: Improve bioavailability, solubility, and stability with cutting-edge processing technologies. As a global partner in drug product development and manufacturing, Glatt Pharmaceutical Services offers tailored solutions to transform your ideas into reality. From concept to commercial production, we support you in creating innovative dosage forms that keep your product competitive post-patent. Ready to explore the possibilities? Let’s work together to redefine your product’s future! #GlattPharma #CDMO #DrugDevelopment #OralSolidDosage #LifecycleManagement Post continued 𝘞𝘩𝘰 𝘸𝘪𝘭𝘭 𝘣𝘦 𝘵𝘩𝘦 𝘣𝘪𝘨𝘨𝘦𝘴𝘵 𝘭𝘰𝘴𝘦𝘳 𝘪𝘯 𝘵𝘩𝘦 𝘤𝘰𝘮𝘪𝘯𝘨 𝘺𝘦𝘢𝘳𝘴? Check the graphic and comment. *The infographic represents US patent expiry and is not exhaustive of all off-patents. Sources: PharmaVoice, BioSpace, Statista

2.300

56 Kommentare

Great insight

6

Transition from expert to a leader It takes work, values, persistence And time ….

15

1 Kommentar

🌟 Women leading change at Sandoz 🌟 Sandoz is leading the way in female representation among major Swiss companies, with 45% of our executives being women, according to an analysis prepared by news wire service AWP Finanznachrichten AG in May this year. And a story published just this week by Swiss national daily Tages-Anzeiger features five women on our executive team driving meaningful change throughout the company 👇 Our corporate culture supports work-life balance, ensuring career progression isn’t hindered by personal responsibilities. Keren Haruvi Snir, President of North America and member of the Sandoz executive team, notes, “I am one and the same person in my private and professional life, and I can stand by that.” Women at Sandoz lead with collaboration and purpose. Chief Scientific Officer Claire D'Abreu-Hayling emphasizes inclusive decision-making, while incoming Chief Commercial Officer Rebecca Guntern believes in keeping patients at the forefront of our work. Chief Legal Officer Ingrid Sollerer aligns her role with her personal values, advocating for affordable medicines. Last but not least, diversity at Sandoz extends beyond gender, incorporating various backgrounds and experiences to fuel innovation. As Chief People Officer Tripti Jha says, “It’s not just about more women, but about more diversity.” Read the full story in German on: https://lnkd.in/dGrW_xBJ Please note a subscription is required to access the full article. #Sandoz #WomenInLeadership #Diversity

621

14 Kommentare

How to conduct successful presentation

2

🔍 Rethinking the 0.05 P-Value Threshold: Time for a Change? 🔍 In the world of statistics, the p-value threshold of 0.05 has long been considered the gold standard for determining statistical significance. However, this conventional benchmark is increasingly under scrutiny. 📊 Why the Controversy? 🧐 🔸 Arbitrariness: Consider a clinical trial testing a new drug. If the p-value is 0.051, it is deemed not statistically significant and the drug might be dismissed. However, if the p-value is 0.049, it is considered significant, and the drug could be approved. This tiny difference can drastically affect decisions, illustrating the arbitrary nature of the 0.05 threshold. 🔸 Misinterpretation: In a psychological study, a p-value of 0.04 might be hailed as evidence that a new therapy is effective. Conversely, a p-value of 0.06 might lead researchers to conclude that the therapy is ineffective. This oversimplifies the results, ignoring the possibility that the therapy might have a meaningful effect that just wasn't detected in this sample. 🔸 Reproducibility Crisis: A famous study claims that a certain type of diet leads to significant weight loss, with a p-value of 0.03. Later attempts to replicate the study find p-values of 0.07 and 0.08, suggesting no significant effect. This inconsistency raises doubts about the original finding's reliability. 🔸 Alternative Approaches: In environmental research, a Bayesian approach might incorporate prior knowledge about pollution levels. Instead of relying solely on a p-value, researchers might use Bayesian methods to update their beliefs based on new data, providing a more nuanced understanding of pollution trends. What are your thoughts on this topic? How do you approach p-values in your research? #statistics #biostatistics #datascience #medical #pharmacy #nursing #dental #medicine #follow #dataanalysis

30

Another book recommendation from my side and many thanks to Piotr Kciuk for the reco in the past. I recommend “Exercised: Why Something We Never Evolved to Do Is Healthy and Rewarding” by Daniel E. Lieberman. Book covers a wide range of exercise-related topics, including: 1. Evolutionary Perspective on Exercise: Lieberman explains how humans evolved to be physically active when necessary, but not to exercise voluntarily for health. 2. Myths about Exercise: The book debunks common myths, such as whether running ruins your knees or if sitting is the new smoking. 3. Types of Physical Activity: It discusses various forms of physical activity, including walking, running, weight lifting, dancing, and High-Intensity Interval Training (HIIT) and their benefits. 4. Health Benefits: Lieberman explores how different types of exercise can reduce the risk of diseases like diabetes and cardiovascular issues. 5. Rest and Recovery: The importance of rest and how it complements physical activity is also highlighted. 6. Making Exercise Enjoyable: The book offers insights on how to make exercise more enjoyable and sustainable, rather than a chore. Definately worth reading!

15

2 Kommentare

CEO Bill Anderson is bringing major changes to the German company’s pharma commercial team, shaking up its structure, personnel and operations. Christine Roth, head of global commercialization at Bayer’s pharmaceutical division, stated in a recent interview: “We are transforming from a company that has been largely focused on hierarchy within functions to an organization—and supporting design—that really focuses on customers and products.” While layoffs across Bayer are not expected to finish until 2025, Roth said headcount reductions in the pharma commercialization unit will largely be done at the beginning of the fourth quarter. "Hats Off to Christine Roth" for moving fast on the restructuring. Speed is of the essence. During the merger of Astra and Zeneca, a guru we worked with preached that speed is of the essence and that it is "better to be roughly right than precisely wrong". However, the journey ahead is long and fraught with risks. Last year, Bayer laid out an ambition to reach $10 billion in revenue from cancer drugs by 2030 and to become a top 10 oncology player. It’s a bold target, considering none of the pharma division’s top 3 products last year were in oncology! Both the revenue target and the goal of being a top 10 oncology player are extremely ambitious. Given my experience in oncology, 51% of me says they won't deliver this. But I could be wrong. I hope they have culled much of the organisation's surplus fat of middle and senior managers. Their organisation just grew and grew without the supporting growth in revenue. But they are not alone. I know of several large pharmaceutical companies that have grown out of proportion to the size of their business—if not globally, certainly in regions such as MEA and especially Africa within that Middle East Region. As many of these begin their five-year planning around now, I would not be surprised if, after several years of failing to deliver the numbers, senior executives decide that a cull is in order to save funds and divert investment to other regions where there is likely to be more bang for their buck. Right now, I'm keen to watch how the new model evolves at Bayer and see if it can make a tangible difference in the numbers to hit their ambitious goals. #bayer #restructure #ssa

1

Bayer got a lot of things wrong in Africa over many years. Earlier this year, they surrendered, threw in the towel and pulled out of Africa in a commercial equivalent of coitus interruptus. Several months later from that surrender, I have to give credit to the CEO Bill Anderson and his Chief Commercial Officer Christine Roth for (a) taking the bold decision to take an axe and cleaver to the organisation and (b) acting with speed. Speed is a critical success factor. Big Pharma lacks agility. Like a huge ocean-going tanker it takes a long time to change direction. Christine Roth has culled much of the surplus fat of junior, middle and senior managers in moving to a new DSO operating model. Only time will tell if the new model works and delivers Bayer's ambition to be a top 10 player in oncology. Reorganisations are rarely carried out well or effectively implemented to create the change that is required. The same applies for mergers and acquisitions. At the merger of Astra with Zeneca back in 1999, we worked with a guru who preached: "Move FAST! Speed is key. Don't deliberate and procrastinate. Focus on getting it 90%. Better to be roughly right than precisely wrong!" I never forgot these teachings. I preach the same to clients - they just procrastinate and worry about being wrong. They freeze with fear! Fight the fear and move fast!

1

Too many meetings? STOP and #act on it: List every meeting you attend and afterwards rate the value you added using the following #scale: 1=It was #essential I was there. 2=It was #helpful I was there. 3=It was of #little value being there. For meetings that consistently #score a 2 or 3, liaise with the meeting organiser and explore a different approach to attending. All the above are difficult to do if you are unclear on your priorities. Can you articulate your priorities for the next month, quarter and year? What’s your longer-term vision for your career? #LeadershipLab @ #AstraZeneca

14

Is recording every moment of your life the future? We’re heading toward a world where every interaction, every movement, everything we do could be captured. Not just by choice—by default. And this data? It will change how AI works, for better or worse. These are just my thoughts, but what if we end up having to record our data just to protect it or to make sure it’s not being used without our knowledge? I’ve been thinking about how this might reshape privacy, safety, and how businesses operate. If you’re curious about where this is going, I’d love to share my latest ideas on this PDF. #AI #DataPrivacy #Future #BusinessThoughts #AIandSociety

27

2 Kommentare

🌟 Midlife Crisis: What Is It? 🌟 Have you ever felt lost or dissatisfied with your life, wondering if this is all there is? You might be experiencing a Midlife Crisis—a period of intense self-reflection, often triggered by the realization of aging and unmet goals. 🤔 🔍 Why Does It Happen? Midlife Crisis occurs when individuals confront their past decisions, feeling anxious about the future, and grappling with the fear of time running out. This leads to regret, impulsive decisions, and strained relationships. ⚠️ Common Consequences: Impulsive career changes 🧳 Strained or broken relationships 💔 Seeking escapism through risky behavior 🎭 A deep sense of dissatisfaction 😟 🛤️ Finding the Path Through Quran & Sunnah: Allah (SWT) reminds us of our purpose and the transient nature of this world: وَمَا هَٰذِهِ ٱلۡحَيَوٰةُ ٱلدُّنۡيَآ إِلَّا لَهۡوٞ وَلَعِبٞۚ وَإِنَّ ٱلدَّارَ ٱلۡأٓخِرَةَ لَهِيَ ٱلۡحَيَوَانُۚ لَوۡ كَانُواْ يَعۡلَمُونَ ٦٤ "This worldly life is no more than play and amusement. But the Hereafter is indeed the real life, if only they knew." (Quran 29:64) "یہ دنیا کی زندگی تو صرف ایک کھیل اور تماشا ہے، اور بے شک آخرت کا گھر ہی اصلی زندگی ہے، اگر وہ جانتے۔" (القرآن 64:29) 🌱 How to Overcome It: - Tawakkul: Trust in Allah’s plan. Know that every stage of life is part of your journey. - Istighfar: Seek forgiveness for past mistakes and move forward. - Purpose: Realign your goals with the purpose of pleasing Allah and prepare for the Hereafter. ✨ Remember: Midlife Crisis can be a turning point toward a more fulfilling and spiritually aligned life. Don’t let it break you; let it shape you into a stronger believer. 💪

5

My main take-away of 2024: we entered the age of AI, and we (humans) need to cultivate and develop 3 irreplaceable competencies : Adaptability, Agency and Self-directed learning • 🔄 Adaptability : Stay open and pivot fast when the world changes. • ✊ Agency : Move beyond complaints —champion the outcomes you desire. • 📚 Self-Directed Learning : Keep acquiring knowledge to stay ahead of the curve. At Sanofi within Business Operations and Global Finance Services, we ensure that our teams #NeverSettle and partner with our internal stakeholders to chase the miracles of science. No matter how powerful technology becomes, these human strengths will determine the impact of our leadership. How will you and your team sharpen these skills? See you in 2025!

65

Super wise words by Rodney W. Zemmel of McKinsey & Company during Fortune Global Forum. In summary, companies tend to overestimate the value of their internal data and are often stuck trying to put most of the resources into data lakes. This is so old school. It was great to hear the refreshing outlook on how generative AI should be deployed for maximum productivity. All photos, copyright of Fortune. And thanks to the wonderful Diane Brady for bringing together the CEO circle - it is a super valuable initiative every progressive CEO should take part in. #Fortune #FortuneGlobal

44

4 Kommentare

I Discovered OpenAI’s Super Secret Roadmap 😱 … Want to Know What It Is? Click Below 👇! ... ... ... So, I was late for my annual tax return 💰 (again—shocking, I know 😮 ). This year, instead of the usual dance of procrastination, panic, and caffeine-fueled Excel wizardry, I turned to my trusty procrastination buddy: ChatGPT. I threw everything at it—random PDFs, receipts, and docs that would make Marie Kondo weep. I asked it to summarize all my expenses into a neat, itemized Excel sheet and calculate what I needed to fill out for my tax return. And boom 💥 —30 seconds later, it was done. What usually takes me hours (or let’s be honest, days, because…procrastination) was done in the time it takes to make a cup of coffee. And here’s the lightbulb 💡 moment: Maybe OpenAI’s secret roadmap is just figuring out what they hate doing the most, procrastinating on it, and then building ChatGPT to fix it. Honestly, not a bad strategy 🤔 . So now, whenever there’s something I really don’t want to do, I just throw it at ChatGPT. And most of the time, it works like magic. Procrastinators of the world, unite (but, like, later)! Who else has discovered the joys of turning life’s annoying tasks into AI experiments? ________ Love ❤️ this post? Add your comments 💭, re-share ♻️ it with your network, follow me 🔔 for more posts like this, and DM me 📩 if you want to deep dive on this topic!

12

1 Kommentar

A little experiment with ChatGPT. Why? Just because. I asked what he/she thinks that our offices look like, he/she replied "one can envision a modern and professional workspace typical of pharmaceutical companies in Switzerland. Such offices often feature contemporary design elements, open-plan layouts to encourage collaboration, dedicated meeting rooms equipped with the latest technology, and areas designed for both focused work and informal discussions." While ChatGPT was slightly off vs. our real offices, we are working hard towards becoming the best we can be. #modernoffice #workplace #reality

31

3 Kommentare